Advertisement


Jason R. Westin, MD, FASCO, on Updated Safety and Efficacy From the SUNMO Trial in LBCL

ASCO 2026

Advertisement

Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
SUNMO is a study comparing a new combination called mosunetuzumab and polatuzumab, or Mosun-Pola. Mosun-Pola is a combination of a bispecific antibody and an antibody-drug conjugate. That combination has looked very promising in patients with relapsed/refractory large B-cell lymphoma, and the SUNMO trial evaluated it in a randomized fashion against R-GemOx, a chemotherapy backbone that's used commonly around the world for patients with relapsed large cell lymphoma. We presented last year the initial results and published them in the Journal of Clinical Oncology, the initial primary analysis. But at this ASCO meeting, we're now presenting an important update to those results. What we've shown with longer follow-up is that Mosun-Pola is still superior to R-GemOx, and we're hopeful this will translate into approvals for Mosun-Pola so that this treatment can be available to patients both within the United States as well as globally if they have relapsed/refractory large B-cell lymphoma. Specifically, what we found in this trial was that in patients who have relapsed large cell lymphoma and are transplant ineligible, the combination of Mosun-Pola had an improvement in overall response rate, complete response rate, progression-free survival, and quality of life for the patients. Patients actually felt better and did better receiving this novel treatment versus chemotherapy. Mosun-Pola is given as an outpatient. The mosunetuzumab part can be given subcutaneously, the polatuzumab part is given intravenously, and it's a fixed-duration treatment. It's not something that has to go on for a long time. It's given for a prescribed number of cycles, and then that stops. And what we found is that it doubled the complete response rate and had a massive improvement in progression-free survival. The interim analysis of overall survival is presented as well, and those data need to mature a bit more to see if there's a true difference in overall survival. But thus far, the results show a very significant improvement in patient outcomes for Mosun-Pola. An important point about the SUNMO trial, as we look at the toxicity profile for Mosun-Pola, is that bispecific antibodies and CAR T-cell therapies have a toxicity called cytokine release syndrome, which can be quite difficult to manage in sites that don't have experience managing this. What we saw for Mosun-Pola was that more than 95% of patients did not have significant cytokine release syndrome, which is a major difference from other bispecific antibodies in the same space. So if community oncologists are looking to choose whether they should use treatment A or treatment B for their patient, the lack of significant toxicities for Mosun-Pola could be a significant advantage for using this regimen over other regimens. That very low rate of cytokine release syndrome will be favorable for patients. So the message that oncologists should take away from this video is that if they're looking for treatments for patients who are ineligible for standard-of-care stem cell transplant with relapsed large cell lymphoma, the bispecific antibody mosunetuzumab and the antibody-drug conjugate polatuzumab, Mosun-Pola, should be an option they should consider for their patients, especially when comparing it to chemotherapy like R-GemOx.

Related Videos

Breast Cancer

Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy

Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500). 

Gastroesophageal Cancer

Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01

Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).

Lung Cancer

Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).

Breast Cancer
Gynecologic Cancers

Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer

Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513). 

Breast Cancer

François-Clément Bidard, MD, PhD, on Advanced Breast Cancer With Emergent ESR1 Mutations: First-Line Option

François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007). 

Advertisement

Advertisement




Advertisement